A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

333 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian flu vaccine with and without adjuvant 1 in healthy, young adults. The study is divided down into Parts A1, A2 and B. Groups within each Part will receive two doses of the assigned test article on Study Days 0 and 21. There will be a Safety Monitoring Committee assessment following Day 7 for each part, prior to allowing vaccination of subjects in subsequent Parts of the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

NCT01596725

Influenza (Pandemic)

COMPLETED PHASE1

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

NCT00812019

Influenza

COMPLETED PHASE1

A/H5N1/LT Dose Ranging Study

NCT00908687

Pandemic Influenza

COMPLETED PHASE2

A/H5N1in Adult - Aventis

NCT00115986

Influenza

COMPLETED PHASE1/PHASE2

A/H5N1 Dose Ranging Study With Adjuvant Patch

NCT00532792

Pandemic Influenza

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza (Pandemic)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Group Type EXPERIMENTAL

Monovalent Avian Influenza VLP (H5N1)

Intervention Type BIOLOGICAL

Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Group B

Group Type EXPERIMENTAL

Monovalent Avian Influenza VLP (H5N1)

Intervention Type BIOLOGICAL

Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Group C

Group Type EXPERIMENTAL

Monovalent Avian Influenza VLP (H5N1); Adjuvant

Intervention Type BIOLOGICAL

Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Group D

Group Type EXPERIMENTAL

Monovalent Avian Influenza VLP (H5N1); Adjuvant

Intervention Type BIOLOGICAL

Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Group E

Group Type EXPERIMENTAL

Monovalent Avian Influenza VLP (H5N1); Adjuvant

Intervention Type BIOLOGICAL

Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Group F

Group Type EXPERIMENTAL

Saline placebo

Intervention Type BIOLOGICAL

Placebo; Intramuscular, deltoid, Day 0 \& Day 21

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Monovalent Avian Influenza VLP (H5N1)

Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Intervention Type BIOLOGICAL

Monovalent Avian Influenza VLP (H5N1)

Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Intervention Type BIOLOGICAL

Monovalent Avian Influenza VLP (H5N1); Adjuvant

Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Intervention Type BIOLOGICAL

Monovalent Avian Influenza VLP (H5N1); Adjuvant

Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Intervention Type BIOLOGICAL

Monovalent Avian Influenza VLP (H5N1); Adjuvant

Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Intervention Type BIOLOGICAL

Saline placebo

Placebo; Intramuscular, deltoid, Day 0 \& Day 21

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy adult male or female, ≥18 and ≤49 years of age,
2. Willing and able to give informed consent prior to study enrollment,
3. Able to comply with study requirements, and
4. Women must have a negative urine pregnancy test prior to each vaccination; will be advised through the Informed Consent process to avoid becoming pregnant over the duration of the study, and must assert that they will employ an effective form of birth control for the duration of the study. Acceptable forms of birth control are: credible history of continuous abstinence from heterosexual activity or prior surgical sterilization, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and intrauterine device (IUD).

Exclusion Criteria

1. Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care. Asymptomatic conditions (e.g., hypertension, dyslipidemia) that are being managed medically and that are not associated with evidence of end-organ damage are not exclusionary provided they are clinically stable (defined as no unscheduled medical interventions or change in medications for cause within 3 months).
2. Any history of jaundice, or of hepatic injury due to drug (prescription, OTC, or illicit) or alcohol use or viral hepatitis; or the presence of hepatitis B surface antigen or hepatitis C antibody at screening.
3. Any grade 1 or higher (as based on the Toxicity Grading Scale \[TGS\]) abnormality in ALT, AST, alkaline phosphatase or total bilirubin levels.
4. Any grade 2 or higher (as based on the TGS) vital sign or clinical laboratory abnormality not specified in criterion 3 above. Note that any abnormal vital sign may be repeated at the Investigator's discretion.
5. Participation in research involving investigational product (drug / biologic / device) within 45 days before planned date of first vaccination.
6. History of a serious reaction to prior influenza vaccination.
7. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine.
8. Received any vaccine in the 4 weeks preceding the study vaccination; or any A/H5N1 avian influenza vaccine at any time.
9. Any known or suspected immunosuppressive condition, acquired or congenital, including HIV infection as determined by history and/or physical examination.
10. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
11. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
12. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature \>38.0°C on the planned day of vaccine administration).
13. Known disturbance of coagulation.
14. Women who are pregnant or breastfeeding, or plan to become pregnant during the study.
15. Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.
16. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes